Compile Data Set for Download or QSAR
Report error Found 37 Enz. Inhib. hit(s) with all data for entry = 7974
TargetMetallo-beta-lactamase type 2(Pseudomonas aeruginosa (g-Proteobacteria))
Infex Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 791617BDBM791617(3-[4-(3-Aminoazetidine-1- carbonyl)phenyl]-1- sulf...)
Affinity DataIC50: 78nMAssay Description:The commercially available HEK293/TREx line (Invitrogen) was stably transfected with a TRPC5 construct and screened by conventional calcium imaging t...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/22/2026
Entry Details US Patent

TargetMetallo-beta-lactamase type 2(Pseudomonas aeruginosa (g-Proteobacteria))
Infex Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 791605BDBM791605((Free Acid): 3-[4-(Dimethylcarbamoyl)phenyl]-1-sul...)
Affinity DataIC50: 111nMAssay Description:The commercially available HEK293/TREx line (Invitrogen) was stably transfected with a TRPC5 construct and screened by conventional calcium imaging t...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/22/2026
Entry Details US Patent

TargetMetallo-beta-lactamase type 2(Pseudomonas aeruginosa (g-Proteobacteria))
Infex Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 791620BDBM791620(3-[4-(Piperazine-1- carbonyl)phenyl]-1- sulfamoyl-...)
Affinity DataIC50: 131nMAssay Description:The commercially available HEK293/TREx line (Invitrogen) was stably transfected with a TRPC5 construct and screened by conventional calcium imaging t...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/22/2026
Entry Details US Patent

TargetMetallo-beta-lactamase type 2(Pseudomonas aeruginosa (g-Proteobacteria))
Infex Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 791638BDBM791638((sodium salt): 3-[6-[(2-Aminoacetyl)amino]-3-pyrid...)
Affinity DataIC50: 162nMAssay Description:To measure cell-based anti-HCV activity of selected compounds of the present invention, replicon cells were seeded at 5000 cells/well in 96-well coll...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/22/2026
Entry Details US Patent

TargetMetallo-beta-lactamase type 2(Pseudomonas aeruginosa (g-Proteobacteria))
Infex Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 791628BDBM791628(3-[3-(2- Aminoethylcarbamoyl) phenyl]-1-sulfamoyl-...)
Affinity DataIC50: 163nMAssay Description:All hERG percentage inhibitions at 10 uM compound concentration were determined by Millipore in a high-throughput cell-based electrophysiology assay ...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/22/2026
Entry Details US Patent

TargetMetallo-beta-lactamase type 2(Pseudomonas aeruginosa (g-Proteobacteria))
Infex Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 791627BDBM791627(3-[4-[4- (Aminomethyl) piperidine-1-carbonyl] phen...)
Affinity DataIC50: 187nMAssay Description:All hERG percentage inhibitions at 10 uM compound concentration were determined by Millipore in a high-throughput cell-based electrophysiology assay ...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/22/2026
Entry Details US Patent

TargetMetallo-beta-lactamase type 2(Pseudomonas aeruginosa (g-Proteobacteria))
Infex Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 791623BDBM791623(3-[4-(Azetidin-3- ylcarbamoyl)phenyl]- 1-sulfamoyl...)
Affinity DataIC50: 200nMAssay Description:The commercially available HEK293/TREx line (Invitrogen) was stably transfected with a TRPC5 construct and screened by conventional calcium imaging t...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/22/2026
Entry Details US Patent

TargetMetallo-beta-lactamase type 2(Pseudomonas aeruginosa (g-Proteobacteria))
Infex Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 791604BDBM791604((Free Acid): 3-[3-(Methylcarbamoyl)phenyl]-1-sulfa...)
Affinity DataIC50: 223nMAssay Description:The commercially available HEK293/TREx line (Invitrogen) was stably transfected with a TRPC5 construct and screened by conventional calcium imaging t...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/22/2026
Entry Details US Patent

TargetMetallo-beta-lactamase type 2(Pseudomonas aeruginosa (g-Proteobacteria))
Infex Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 791637BDBM791637((Free Acid): 3-[4-[Methyl-[2-(methylamino)ethyl]ca...)
Affinity DataIC50: 248nMAssay Description:To measure cell-based anti-HCV activity of selected compounds of the present invention, replicon cells were seeded at 5000 cells/well in 96-well coll...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/22/2026
Entry Details US Patent

TargetMetallo-beta-lactamase type 2(Pseudomonas aeruginosa (g-Proteobacteria))
Infex Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 791626BDBM791626(3-[4-[[(1S,5R)-3- Azabicyclo[3.1.0] hexan-6- yl]ca...)
Affinity DataIC50: 273nMAssay Description:All hERG percentage inhibitions at 10 uM compound concentration were determined by Millipore in a high-throughput cell-based electrophysiology assay ...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/22/2026
Entry Details US Patent

TargetMetallo-beta-lactamase type 2(Pseudomonas aeruginosa (g-Proteobacteria))
Infex Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 791618BDBM791618((Free Acid): 3-[4-[Methyl-[2-(methylamino)ethyl]ca...)
Affinity DataIC50: 319nMAssay Description:The commercially available HEK293/TREx line (Invitrogen) was stably transfected with a TRPC5 construct and screened by conventional calcium imaging t...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/22/2026
Entry Details US Patent

TargetMetallo-beta-lactamase type 2(Pseudomonas aeruginosa (g-Proteobacteria))
Infex Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 791609BDBM791609(3-[4-[2-(Dimethylamino) ethylcarbamoyl]phenyl]-1- ...)
Affinity DataIC50: 373nMAssay Description:The commercially available HEK293/TREx line (Invitrogen) was stably transfected with a TRPC5 construct and screened by conventional calcium imaging t...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/22/2026
Entry Details US Patent

TargetMetallo-beta-lactamase type 2(Pseudomonas aeruginosa (g-Proteobacteria))
Infex Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 791610BDBM791610(3-[4-(2-Acetamidoethyl- carbamoyl)phenyl]-1- sulfa...)
Affinity DataIC50: 374nMAssay Description:The commercially available HEK293/TREx line (Invitrogen) was stably transfected with a TRPC5 construct and screened by conventional calcium imaging t...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/22/2026
Entry Details US Patent

TargetMetallo-beta-lactamase type 2(Pseudomonas aeruginosa (g-Proteobacteria))
Infex Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 791640BDBM791640((HCl salt): 3-[6-(2-Aminoethylamino)-3-pyridyl]-1-...)
Affinity DataIC50: 377nMAssay Description:To measure cell-based anti-HCV activity of selected compounds of the present invention, replicon cells were seeded at 5000 cells/well in 96-well coll...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/22/2026
Entry Details US Patent

TargetMetallo-beta-lactamase type 2(Pseudomonas aeruginosa (g-Proteobacteria))
Infex Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 791616BDBM791616(3-[4-[2-(2-Oxoimidazolidin- 1-yl)ethylcarbamoyl]ph...)
Affinity DataIC50: 394nMAssay Description:The commercially available HEK293/TREx line (Invitrogen) was stably transfected with a TRPC5 construct and screened by conventional calcium imaging t...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/22/2026
Entry Details US Patent

TargetMetallo-beta-lactamase type 2(Pseudomonas aeruginosa (g-Proteobacteria))
Infex Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 791636BDBM791636((Free Acid): 3-[1-(2-Aminoethyl)-4-piperidyl]-1-su...)
Affinity DataIC50: 399nMAssay Description:To measure cell-based anti-HCV activity of selected compounds of the present invention, replicon cells were seeded at 5000 cells/well in 96-well coll...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/22/2026
Entry Details US Patent

TargetMetallo-beta-lactamase type 2(Pseudomonas aeruginosa (g-Proteobacteria))
Infex Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 791608BDBM791608(3-[4-[(2-Amino-2-oxo- ethyl)carbamoyl]phenyl]- 1-s...)
Affinity DataIC50: 405nMAssay Description:The commercially available HEK293/TREx line (Invitrogen) was stably transfected with a TRPC5 construct and screened by conventional calcium imaging t...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/22/2026
Entry Details US Patent

TargetMetallo-beta-lactamase type 2(Pseudomonas aeruginosa (g-Proteobacteria))
Infex Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 791624BDBM791624(3-[4-(4- Piperidylcarbamoyl) phenyl]-1-sulfamoyl- ...)
Affinity DataIC50: 410nMAssay Description:All hERG percentage inhibitions at 10 uM compound concentration were determined by Millipore in a high-throughput cell-based electrophysiology assay ...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/22/2026
Entry Details US Patent

TargetMetallo-beta-lactamase type 2(Pseudomonas aeruginosa (g-Proteobacteria))
Infex Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 791619BDBM791619(3-[4-(2-Aminoethyl- carbamoyl)phenyl]-1- sulfamoyl...)
Affinity DataIC50: 420nMAssay Description:The commercially available HEK293/TREx line (Invitrogen) was stably transfected with a TRPC5 construct and screened by conventional calcium imaging t...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/22/2026
Entry Details US Patent

TargetMetallo-beta-lactamase type 2(Pseudomonas aeruginosa (g-Proteobacteria))
Infex Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 791629BDBM791629((Free Acid): 3-[1-Acetyl-3-piperidyl]-1-sulfamoyl-...)
Affinity DataIC50: 433nMAssay Description:The ability of representative disclosed to block influenza infection was assessed in a cell-based assay using A549 human epithelial cells (ATCC CCL-1...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/22/2026
Entry Details US Patent

TargetMetallo-beta-lactamase type 2(Pseudomonas aeruginosa (g-Proteobacteria))
Infex Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 791611BDBM791611(3-[4-(3-Hydroxypropyl- carbamoyl)phenyl]-1- sulfam...)
Affinity DataIC50: 527nMAssay Description:The commercially available HEK293/TREx line (Invitrogen) was stably transfected with a TRPC5 construct and screened by conventional calcium imaging t...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/22/2026
Entry Details US Patent

TargetMetallo-beta-lactamase type 2(Pseudomonas aeruginosa (g-Proteobacteria))
Infex Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 791613BDBM791613(3-[4-[[(2R)-2,3- Dihydroxypropyl]carbamoyl] phenyl...)
Affinity DataIC50: 566nMAssay Description:The commercially available HEK293/TREx line (Invitrogen) was stably transfected with a TRPC5 construct and screened by conventional calcium imaging t...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/22/2026
Entry Details US Patent

TargetMetallo-beta-lactamase type 2(Pseudomonas aeruginosa (g-Proteobacteria))
Infex Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 791634BDBM791634(3-[1-[(2S)-Pyrrolidine-2 carbonyl]-4-piperidyl]-1-...)
Affinity DataIC50: 568nMAssay Description:The ability of representative disclosed to block influenza infection was assessed in a cell-based assay using A549 human epithelial cells (ATCC CCL-1...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/22/2026
Entry Details US Patent

TargetMetallo-beta-lactamase type 2(Pseudomonas aeruginosa (g-Proteobacteria))
Infex Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 791615BDBM791615(3-[4-[2-(2-Oxopyrrolidin-1- yl)ethylcarbamoyl]phen...)
Affinity DataIC50: 623nMAssay Description:The commercially available HEK293/TREx line (Invitrogen) was stably transfected with a TRPC5 construct and screened by conventional calcium imaging t...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/22/2026
Entry Details US Patent

TargetMetallo-beta-lactamase type 2(Pseudomonas aeruginosa (g-Proteobacteria))
Infex Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 791607BDBM791607(3-[4-(Carboxymethyl- carbamoyl)phenyl]-1- sulfamoy...)
Affinity DataIC50: 650nMAssay Description:The commercially available HEK293/TREx line (Invitrogen) was stably transfected with a TRPC5 construct and screened by conventional calcium imaging t...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/22/2026
Entry Details US Patent

TargetMetallo-beta-lactamase type 2(Pseudomonas aeruginosa (g-Proteobacteria))
Infex Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 791625BDBM791625(3-[4-[[(3R,4R)-3- Hydroxy-4- piperidyl]carbamoyl] ...)
Affinity DataIC50: 652nMAssay Description:All hERG percentage inhibitions at 10 uM compound concentration were determined by Millipore in a high-throughput cell-based electrophysiology assay ...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/22/2026
Entry Details US Patent

TargetMetallo-beta-lactamase type 2(Pseudomonas aeruginosa (g-Proteobacteria))
Infex Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 791606BDBM791606(3-[4-(Cyanomethyl- carbamoyl)phenyl]-1- sulfamoyl-...)
Affinity DataIC50: 843nMAssay Description:The commercially available HEK293/TREx line (Invitrogen) was stably transfected with a TRPC5 construct and screened by conventional calcium imaging t...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/22/2026
Entry Details US Patent

TargetMetallo-beta-lactamase type 2(Pseudomonas aeruginosa (g-Proteobacteria))
Infex Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 791612BDBM791612(3-[4-[[2-Hydroxy-1- (hydroxymethyl)ethyl] carbamoy...)
Affinity DataIC50: 1.06E+3nMAssay Description:The commercially available HEK293/TREx line (Invitrogen) was stably transfected with a TRPC5 construct and screened by conventional calcium imaging t...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/22/2026
Entry Details US Patent

TargetMetallo-beta-lactamase type 2(Pseudomonas aeruginosa (g-Proteobacteria))
Infex Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 791622BDBM791622((Free Acid): 3-[4-[2-(Ethylamino)ethylcarbamoyl]ph...)
Affinity DataIC50: 1.06E+3nMAssay Description:The commercially available HEK293/TREx line (Invitrogen) was stably transfected with a TRPC5 construct and screened by conventional calcium imaging t...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/22/2026
Entry Details US Patent

TargetMetallo-beta-lactamase type 2(Pseudomonas aeruginosa (g-Proteobacteria))
Infex Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 791632BDBM791632(3-[1-[(2S)-2- Aminopropanoyl]-4- piperidyl]-1-sulf...)
Affinity DataIC50: 1.48E+3nMAssay Description:The ability of representative disclosed to block influenza infection was assessed in a cell-based assay using A549 human epithelial cells (ATCC CCL-1...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/22/2026
Entry Details US Patent

TargetMetallo-beta-lactamase type 2(Pseudomonas aeruginosa (g-Proteobacteria))
Infex Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 791635BDBM791635(3-[1-(Azetidine-3- carbonyl)-4-piperidyl]-1- sulfa...)
Affinity DataIC50: 1.55E+3nMAssay Description:To measure cell-based anti-HCV activity of selected compounds of the present invention, replicon cells were seeded at 5000 cells/well in 96-well coll...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/22/2026
Entry Details US Patent

TargetMetallo-beta-lactamase type 2(Pseudomonas aeruginosa (g-Proteobacteria))
Infex Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 791633BDBM791633(3-[1-[(2S)-2-Amino-3- hydroxy-propanoyl]-4- piperi...)
Affinity DataIC50: 1.57E+3nMAssay Description:The ability of representative disclosed to block influenza infection was assessed in a cell-based assay using A549 human epithelial cells (ATCC CCL-1...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/22/2026
Entry Details US Patent

TargetMetallo-beta-lactamase type 2(Pseudomonas aeruginosa (g-Proteobacteria))
Infex Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 791630BDBM791630(3-[1-Acetylpyrrolidin-3-yl]- 1-sulfamoyl-pyrrole-2...)
Affinity DataIC50: 1.61E+3nMAssay Description:The ability of representative disclosed to block influenza infection was assessed in a cell-based assay using A549 human epithelial cells (ATCC CCL-1...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/22/2026
Entry Details US Patent

TargetMetallo-beta-lactamase type 2(Pseudomonas aeruginosa (g-Proteobacteria))
Infex Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 791631BDBM791631((Free Acid): 3-[1-(2-Aminoacetyl)-3-piperidyl]-1-s...)
Affinity DataIC50: 1.76E+3nMAssay Description:The ability of representative disclosed to block influenza infection was assessed in a cell-based assay using A549 human epithelial cells (ATCC CCL-1...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/22/2026
Entry Details US Patent

TargetMetallo-beta-lactamase type 2(Pseudomonas aeruginosa (g-Proteobacteria))
Infex Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 791614BDBM791614(3-[4-(2-Morpholinoethyl- carbamoyl)phenyl]-1- sulf...)
Affinity DataIC50: 1.79E+3nMAssay Description:The commercially available HEK293/TREx line (Invitrogen) was stably transfected with a TRPC5 construct and screened by conventional calcium imaging t...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/22/2026
Entry Details US Patent

TargetMetallo-beta-lactamase type 2(Pseudomonas aeruginosa (g-Proteobacteria))
Infex Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 791639BDBM791639(3-[6-(3- Aminopropanoylamino)-3- pyridyl]-1-sulfam...)
Affinity DataIC50: 2.49E+3nMAssay Description:To measure cell-based anti-HCV activity of selected compounds of the present invention, replicon cells were seeded at 5000 cells/well in 96-well coll...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/22/2026
Entry Details US Patent

TargetMetallo-beta-lactamase type 2(Pseudomonas aeruginosa (g-Proteobacteria))
Infex Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 791621BDBM791621(3-[3-(3-Aminoazetidine- 1-carbonyl)phenyl]-1- sulf...)
Affinity DataIC50: 3.33E+3nMAssay Description:The commercially available HEK293/TREx line (Invitrogen) was stably transfected with a TRPC5 construct and screened by conventional calcium imaging t...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
6/22/2026
Entry Details US Patent